Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)
 
 • Company Description   
Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.99 Daily Weekly Monthly
20 Day Moving Average: 509,411 shares
Shares Outstanding: 15.03 (millions)
Market Capitalization: $29.92 (millions)
Beta: -0.07
52 Week High: $3.35
52 Week Low: $0.68
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.30% -29.09%
12 Week 2.05% -5.27%
Year To Date -13.10% -20.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11400 WEST OLYMPIC BLVD SUITE 200
-
LOS ANGELES,CA 90064
USA
ph: 310-651-8041
fax: -
None http://www.immixbio.com
 
 • General Corporate Information   
Officers
Ilya Rachman - Chief Executive Officer and Chairman
Gabriel Morris - Chief Financial Officer and Director
Jason Hsu - Director
Magda Marquet - Director
Helen C. Adams - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258H106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/22
Next Expected EPS Date: 06/02/23
Share - Related Items
Shares Outstanding: 15.03
Most Recent Split Date: (:1)
Beta: -0.07
Market Capitalization: $29.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/02/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.36
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -62.89
12/31/22 - -48.65
09/30/22 - -149.98
ROA
03/31/23 - -58.18
12/31/22 - -46.10
09/30/22 - -145.58
Current Ratio
03/31/23 - 8.85
12/31/22 - 11.70
09/30/22 - 26.92
Quick Ratio
03/31/23 - 8.85
12/31/22 - 11.70
09/30/22 - 26.92
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - 0.78
12/31/22 - 0.94
09/30/22 - 1.20
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©